Mbio Diagnostics, Inc.

BOULDER, CO 80303

SBIR Award Summary

Total Number of Awards 11
Total Value of Awards $6.49MM
First Award Date 07/03/10
Most Recent Award Date 09/12/17

Key Personnel

Last Name Name Awards Contact
Lochhead Michael J Lochhead 9 Message
Myatt Christopher John Myatt 3

11 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/12/17 - 08/31/18

Sepsis is a devastating cause of morbidity and mortality in intensive care units (ICUs), with estimates of U.S. incidence ranging from 894,000 to 3.1 million cases annually. The heterogeneity of clinical presentation (etiology, patient history, severity, etc.) creates a major challenge for patient management and has significantly complicated dev...

Phase 1 SBIR

Agency: National Science Foundation
Topic: CT
Budget: 07/01/16 - 06/30/17

The broader impact/commercial potential of this Small Business Innovation Research Phase I project will be to initiate development of an effective technology that will enable users in the field to perform laboratory-quality cyanotoxin testing to help protect drinking water, monitor commercial food resources, and provide critical data for ecosyst...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based, 4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/08/13 - 06/30/14

DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based, 4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 03/01/13 - 02/28/14

DESCRIPTION (provided by applicant): The overall goal of this project is to develop and commercialize a simple cell counter for routine enumeration of CD4 cells for management of HIV-infected individuals. HIV-1 mediated CD4 cell destruction is the central immunologic feature of HIV-1 infection. Thus, the CD4 count is a critical measurement in i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 03/01/12 - 02/28/13

DESCRIPTION (provided by applicant): The overall goal of this project is to develop and commercialize a simple cell counter for routine enumeration of CD4 cells for management of HIV-infected individuals. HIV-1 mediated CD4 cell destruction is the central immunologic feature of HIV-1 infection. Thus, the CD4 count is a critical measurement in i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/11 - 08/31/13

DESCRIPTION (provided by applicant): Diagnosis and medical management of HIV-infected individuals is significantly enhanced if one can simultaneously define the subset of the most common co-infections for which patients are at risk. Unfortunately, running such a series of parallel diagnostic tests is cost prohibitive, particularly in low-resourc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/10/11 - 07/31/12

DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based, 4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): Accurate counts of helper T cells and related lymphocytes are critical in decisions about HIV status and antiretroviral therapies. Flow cytometry is the standard method of cell counting, but the majority of the 30 to 40 million infected people worldwide are in resource-limited areas and do not have access to ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): Diagnosis and medical management of HIV-infected individuals is significantly enhanced if one can simultaneously define the subset of the most common co-infections for which patients are at risk. Unfortunately, running such a series of parallel diagnostic tests is cost prohibitive, particularly in low-resourc...

Load More